HRP20230445T1 - Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja - Google Patents
Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja Download PDFInfo
- Publication number
- HRP20230445T1 HRP20230445T1 HRP20230445TT HRP20230445T HRP20230445T1 HR P20230445 T1 HRP20230445 T1 HR P20230445T1 HR P20230445T T HRP20230445T T HR P20230445TT HR P20230445 T HRP20230445 T HR P20230445T HR P20230445 T1 HRP20230445 T1 HR P20230445T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- use according
- chronic cough
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title claims 12
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 16
- 150000003839 salts Chemical class 0.000 claims 16
- 208000013116 chronic cough Diseases 0.000 claims 9
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 230000001537 neural effect Effects 0.000 claims 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (11)
1. Spoj koji je
[image]
ili
njegova farmaceutski prihvatljiva sol za primjenu u liječenju kroničnog kašlja ili neuronske hiperosjetljivosti koja je u osnovi akutnog, subakutnog ili kroničnog kašlja, pri čemu se spoj ili njegova farmaceutski prihvatljiva sol administriraju u opsegu od 45-55 mg dva puta na dan.
2. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 1, pri čemu se spoj ili njegova farmaceutski prihvatljiva sol administriraju u dozi od 45mg dva puta na dan.
3. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 1, pri čemu se spoj ili njegova farmaceutski prihvatljiva sol administriraju u dozi od 50mg dva puta na dan.
4. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema patentnom zahtjevu 1, pri čemu se spoj ili njegova farmaceutski prihvatljiva sol administriraju u dozi od 55mg dva puta na dan.
5. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem patentnom zahtjevu, pri čemu je primjena liječenje kroničnog kašlja.
6. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem od patentnih zahtjeva 1 do 4, pri čemu je primjena liječenje neuronske hiperosjetljivosti koja je u osnovi akutnog, subakutnog ili kroničnog kašlja.
7. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu kronični kašalj je idiopatski ili kašalj otporan na liječenje.
8. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu se spoj ili njegova sol administriraju tokom dana, tjedana, mjeseci ili godina, uključujući neograničeno.
9. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu kronični kašalj je refraktorni kronični kašalj.
10. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu je kronični kašalj reduciran za oko 75%.
11. Spoj ili njegova farmaceutski prihvatljiva sol za primjenu prema bilo kojem prethodnom patentnom zahtjevu, pri čemu kronični kašalj je dnevni kašalj.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562234584P | 2015-09-29 | 2015-09-29 | |
| US201662336381P | 2016-05-13 | 2016-05-13 | |
| PCT/US2016/053223 WO2017058645A1 (en) | 2015-09-29 | 2016-09-23 | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| EP16852340.5A EP3355889B1 (en) | 2015-09-29 | 2016-09-23 | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230445T1 true HRP20230445T1 (hr) | 2023-07-21 |
Family
ID=58424436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230445TT HRP20230445T1 (hr) | 2015-09-29 | 2016-09-23 | Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11260056B2 (hr) |
| EP (2) | EP4215182A1 (hr) |
| JP (1) | JP6877441B2 (hr) |
| KR (1) | KR20180054843A (hr) |
| AU (1) | AU2016330466B2 (hr) |
| CA (1) | CA2998742C (hr) |
| DK (1) | DK3355889T3 (hr) |
| ES (1) | ES2942711T3 (hr) |
| FI (2) | FI3355889T3 (hr) |
| HR (1) | HRP20230445T1 (hr) |
| HU (1) | HUE061764T2 (hr) |
| LT (1) | LT3355889T (hr) |
| MX (1) | MX2018003893A (hr) |
| NL (1) | NL301260I2 (hr) |
| PL (1) | PL3355889T3 (hr) |
| PT (1) | PT3355889T (hr) |
| RS (1) | RS64155B1 (hr) |
| SI (1) | SI3355889T1 (hr) |
| WO (1) | WO2017058645A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2021120039A (ru) * | 2016-12-20 | 2021-08-03 | Эфферент Фармасьютикалз, Инк. | Кристаллические соли и полиморфы антагониста p2x3 |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CA3100099A1 (en) * | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| JP6725188B1 (ja) | 2018-10-05 | 2020-07-15 | 塩野義製薬株式会社 | 慢性咳嗽治療用医薬 |
| CN114007619A (zh) * | 2019-04-30 | 2022-02-01 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物治疗咳嗽的方法 |
| WO2020239951A1 (en) | 2019-05-31 | 2020-12-03 | Chiesi Farmaceutici S.P.A. | Amino quinazoline derivatives as p2x3 inhibitors |
| EP3976609A1 (en) | 2019-05-31 | 2022-04-06 | Chiesi Farmaceutici S.p.A. | Pyridopyrimidines derivatives as p2x3 inhibitors |
| TW202124373A (zh) * | 2019-09-19 | 2021-07-01 | 日商塩野義製藥股份有限公司 | 1，3，5-三衍生物或其溶劑合物之結晶及其製造方法 |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| KR20230113309A (ko) | 2020-11-27 | 2023-07-28 | 키에시 파르마슈티시 엣스. 피. 에이. | P2x3 억제제로서 아미노 퀴나졸린 유도체 |
| CA3196337A1 (en) | 2020-11-27 | 2022-06-02 | Claudio FIORELLI | (aza)quinoline 4-amines derivatives as p2x3 inhibitors |
| WO2022112493A1 (en) | 2020-11-27 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | Phthalazine derivatives as p2x3 inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1725540E (pt) | 2004-03-05 | 2012-11-29 | Hoffmann La Roche | Diaminopirimidinas como antagonistas de p2x3 e p2x2/3 |
| JP2008507368A (ja) | 2004-07-22 | 2008-03-13 | デュスカ サイエンティフィック カンパニー | 肺疾患を診断、モニタリングおよび治療するための方法 |
| CN101253158B (zh) | 2005-09-01 | 2013-07-10 | 弗·哈夫曼-拉罗切有限公司 | 合成芳氧基二氨基嘧啶类化合物的方法 |
| CA2619919C (en) | 2005-09-01 | 2014-04-01 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| WO2007025925A1 (en) | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| ES2466667T3 (es) * | 2006-10-04 | 2014-06-10 | F. Hoffmann-La Roche Ag | Proceso para síntesis de derivados de fenoxi diaminopirimidina |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| EP3865134A1 (en) * | 2013-08-23 | 2021-08-18 | Afferent Pharmaceuticals Inc. | Methods of using diaminopyrimidine p2x3 and p2x 2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
-
2016
- 2016-09-23 ES ES16852340T patent/ES2942711T3/es active Active
- 2016-09-23 PT PT168523405T patent/PT3355889T/pt unknown
- 2016-09-23 JP JP2018535821A patent/JP6877441B2/ja active Active
- 2016-09-23 US US15/764,174 patent/US11260056B2/en active Active
- 2016-09-23 SI SI201631686T patent/SI3355889T1/sl unknown
- 2016-09-23 RS RS20230321A patent/RS64155B1/sr unknown
- 2016-09-23 CA CA2998742A patent/CA2998742C/en active Active
- 2016-09-23 DK DK16852340.5T patent/DK3355889T3/da active
- 2016-09-23 HU HUE16852340A patent/HUE061764T2/hu unknown
- 2016-09-23 HR HRP20230445TT patent/HRP20230445T1/hr unknown
- 2016-09-23 MX MX2018003893A patent/MX2018003893A/es unknown
- 2016-09-23 PL PL16852340.5T patent/PL3355889T3/pl unknown
- 2016-09-23 AU AU2016330466A patent/AU2016330466B2/en active Active
- 2016-09-23 LT LTEPPCT/US2016/053223T patent/LT3355889T/lt unknown
- 2016-09-23 FI FIEP16852340.5T patent/FI3355889T3/fi active
- 2016-09-23 KR KR1020187011747A patent/KR20180054843A/ko not_active Application Discontinuation
- 2016-09-23 WO PCT/US2016/053223 patent/WO2017058645A1/en active Application Filing
- 2016-09-23 EP EP23155536.8A patent/EP4215182A1/en active Pending
- 2016-09-23 EP EP16852340.5A patent/EP3355889B1/en active Active
-
2022
- 2022-01-24 US US17/582,485 patent/US20220143015A1/en active Pending
-
2024
- 2024-03-04 NL NL301260C patent/NL301260I2/nl unknown
- 2024-03-13 FI FIC20240006C patent/FIC20240006I1/fi unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2942711T3 (es) | 2023-06-06 |
| JP2018529776A (ja) | 2018-10-11 |
| EP4215182A1 (en) | 2023-07-26 |
| AU2016330466B2 (en) | 2021-01-28 |
| EP3355889A4 (en) | 2019-05-22 |
| CA2998742A1 (en) | 2017-04-06 |
| NL301260I2 (nl) | 2024-03-25 |
| CA2998742C (en) | 2023-08-29 |
| FIC20240006I1 (fi) | 2024-03-13 |
| HUE061764T2 (hu) | 2023-08-28 |
| EP3355889B1 (en) | 2023-02-15 |
| SI3355889T1 (sl) | 2023-07-31 |
| AU2016330466A1 (en) | 2018-03-29 |
| RS64155B1 (sr) | 2023-05-31 |
| US11260056B2 (en) | 2022-03-01 |
| US20220143015A1 (en) | 2022-05-12 |
| DK3355889T3 (da) | 2023-05-15 |
| US20180280388A1 (en) | 2018-10-04 |
| EP3355889A1 (en) | 2018-08-08 |
| KR20180054843A (ko) | 2018-05-24 |
| PT3355889T (pt) | 2023-04-26 |
| MX2018003893A (es) | 2018-06-22 |
| JP6877441B2 (ja) | 2021-05-26 |
| LT3355889T (lt) | 2023-05-10 |
| FI3355889T3 (fi) | 2023-05-15 |
| WO2017058645A1 (en) | 2017-04-06 |
| PL3355889T3 (pl) | 2023-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230445T1 (hr) | Modulatori diaminopirimidin p2x3 i p2x2/3 receptora za primjenu u liječenju kašlja | |
| HRP20191299T1 (hr) | Formulacije protutijela | |
| BR112015022417A2 (pt) | métodos e composições para inibição de proteínas contendo bromodomínio | |
| BR112015026549A2 (pt) | forma de dosagem à prova de violação contendo uma ou mais partículas | |
| HRP20220759T1 (hr) | Pripravci i postupci koji ih koriste za liječenje neurodegenerativne i mitohondrijske bolesti | |
| HRP20212010T1 (hr) | Liječenje kolestatskog pruritusa sa seladelparom | |
| BR112016012666A2 (pt) | conjugado, anticorpos, formulação farmacêutica e usos de conjugado | |
| BR112018068278A2 (pt) | derivado de 3-desóxi e suas composições farmacêuticas | |
| SI2849758T1 (en) | COMPOSITION CONTAINING ZOLEDORNIH ALI OR RELATED COMPOUNDS FOR THE PREPARATION OF INHALANE PATIENTS AND RELATED STATIONS | |
| HRP20201627T1 (hr) | Postupak liječenja s tradipitantom | |
| HRP20220903T1 (hr) | Seladelpar za liječenje primarnog bilijarnog kolangitisa | |
| BR112014022780A2 (pt) | composto modulador de receptor de fígado x, composição farmacêutica que o compreende e seu uso | |
| PE20180411A1 (es) | Formulaciones farmaceuticas que comprenden tenofovir y emtricitabina | |
| HRP20230861T1 (hr) | PROTUTIJELA PROTIV PEPTIDA N3pGLU AMILOIDA BETA I NJIHOVA UPOTREBA | |
| HRP20161295T1 (hr) | Primjena antitumorskog sredstva | |
| HRP20231716T1 (hr) | Pripravci inhibitora dopa dekarboksilaze | |
| BR112017028140A2 (pt) | formulações farmacêuticas | |
| HRP20210552T1 (hr) | Liječenje multiplog mijeloma (mm) | |
| HRP20210207T1 (hr) | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta | |
| BR112015015872A2 (pt) | composição de tratamento oral | |
| PH12015501554A1 (en) | Sustained-release lipid pre-concentrate of anionic pharmacologically active substances and pharmaceutical composition comprising the same | |
| HRP20230523T1 (hr) | Antitumorski agens i sredstvo za poboljšavanje antitumorskog efekta | |
| BR112012006955A2 (pt) | agente de acabamento mate ou fosco para vernizes de uv | |
| BR112016028922A8 (pt) | composição na forma de partículas compactadas e uso da mesma | |
| BR112015014092A2 (pt) | administração oral transmucosal de acetato de glatirâmer |